Development of Next-Generation NK Cell Optimized Chimeric Antigen Receptors (CARs) for iPSC-Derived NK Cell Therapies Targeting Both Solid and Liquid Tumors

嵌合抗原受体 NKG2D公司 细胞因子释放综合征 免疫疗法 癌症研究 癌症免疫疗法 免疫学 医学 生物 免疫系统 细胞毒性T细胞 生物化学 体外
作者
Lee Swanson,Kenyon Lyon,Wael Tadros,Mafalda Loreti,Tammy Babin,B. Blair,Max Schabla,Paschalis Sideras,Dan S. Kaufman,Robert Hollingsworth,Huang Zhu
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 4540-4541 被引量:2
标识
DOI:10.1182/blood-2022-163884
摘要

Chimeric Antigen Receptor (CAR) immunotherapy has transformed cancer therapeutics and has been successful in treating hematologic malignancies. To date, autologous T-cell therapy has been the major focus of CAR research and product development but has several limitations including high-cost and complexity of manufacturing, donor-to-donor variability, and severe toxicities in some patients. Allogenic natural killer (NK) cell therapies have also been shown to mount potent responses against hematologic malignancies, but unlike T-cell therapies are less likely to cause high-grade toxicities, such as cytokine release syndrome, neurotoxicity, or graft-vs-host-disease (GVHD), and therefore may serve as a preferred platform for CAR-enabled therapies. Several groups have demonstrated the clinical efficacy of CAR-expressing allogenic NK cells using CARs developed for T-cells (i.e., CD28 co-stimulatory domains). However, recent studies using NK cell activating receptor signaling modules (i.e., NKG2D and 2B4) as CAR signaling domains demonstrate increased activity compared to T-cell CARs, demonstrating the utility of NK optimized CARs. In addition, our previous studies showed that knocking out CIS (encoded by CISH gene), a key intracellular checkpoint of NK cell activation, in iPSC-derived NK cells (CISH KO iNK) significantly improved their anti-tumor activity, in vivo persistence, metabolic fitness, polyfunctionality and resistance to cell exhaustion. The goal of this study was to develop next-generation NK cell-optimized CARs designed to improve targeting and potency of our CISH KO iNK cell therapies against both hematologic malignancies and solid tumors. To achieve this, we developed a screening platform to identify novel CAR signaling domains derived from an array of immune cell signaling modules (Figure 1). First, we constructed a library of 44 CAR constructs (targeting CD19) containing signaling modules from diverse immune cell signaling receptors including NK cell activating receptors, cytokine receptors, and integrins. Next, we developed an efficient CAR expression protocol in iPSC-derived NK cells that yields high CAR expression (>75% CAR+) while maintaining high viability (>90%). We then screened for CAR activity using two co-culture target cell killing assays (eSight impedance assay and Caspase 3/7 killing assay) to test activity against two NK cell resistant CD19+ target cell lines (Raji and SupB15). Our screen identified 7 CAR signaling domains that performed better than both a T-cell CAR (CD28-CD28-CD3ζ) and previously reported NK cell optimized CARs (NKG2D-2B4-CD3ζ, CD28-OX40-CD3ζ, and CD28-OX40L-CD3ζ). These results were consistent across both functional assays and both target cell lines tested. To demonstrate the broad applicability of our top CAR construct (SLNK12) we generated SLNK12-CARs paired with antigen binding domains against various tumor antigens such as CD20, HER-2 etc. We confirmed that SLNK12-CARs potently kill target cell lines regardless of the antigen being targeted. To stringently test SLNK12-CAR potency, we conducted limiting dilution killing assays, serial killing assays, and 3D tumor spheroid killing assays. In all formats SLNK12-CAR iNK cells demonstrated better or comparable killing compared to previously reported NK cell optimized CAR NKG2D-2B4-CD3ζ (Figure 2). Current work is focused on validating our SLNK12-CARs using in vivo models. Overall, we have successfully developed a CAR screening platform in a therapeutically relevant allogenic cell source and have identified NK cell optimized CARs that enable increased potency of NK cells against both solid and liquid tumor cell lines including SKOV-3, BT474, SUP-B15, MOLT-4, Raji etc. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
AKTAO发布了新的文献求助10
刚刚
wwwww发布了新的文献求助20
1秒前
1秒前
Echo发布了新的文献求助10
1秒前
2秒前
lizh187完成签到 ,获得积分10
3秒前
JasonChan完成签到 ,获得积分10
3秒前
3秒前
Jasper的应助被oo采纳,获得30
4秒前
英姑的应助被辰侑依采纳,获得10
4秒前
我我发布了新的文献求助10
4秒前
4秒前
5秒前
天天发布了新的文献求助10
5秒前
Owen的应助被温凛采纳,获得10
5秒前
强强发布了新的文献求助10
6秒前
6秒前
6秒前
袁rrrr完成签到,获得积分10
6秒前
ww完成签到,获得积分10
6秒前
6秒前
AAA麻精批发完成签到,获得积分10
7秒前
8秒前
巴拉巴拉发布了新的文献求助10
9秒前
111发布了新的文献求助30
9秒前
9秒前
悦耳的城发布了新的文献求助10
10秒前
花青素ii发布了新的文献求助10
10秒前
英姑的应助被李峥采纳,获得10
11秒前
kychao完成签到,获得积分10
12秒前
liugm发布了新的文献求助10
12秒前
12秒前
幻文悠发布了新的文献求助10
12秒前
英俊的铭的应助被快乐的忆安采纳,获得20
12秒前
找回自己发布了新的文献求助10
13秒前
13秒前
科研通AI2S的应助被yxxxxx采纳,获得10
14秒前
秋风的应助被仁爱的沁采纳,获得100
14秒前
斯文败类的应助被我我采纳,获得30
14秒前
顾矜的应助被SHN采纳,获得20
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193684
求助须知:如何正确求助?哪些是违规求助? 9579855
关于积分的说明 21867890
捐赠科研通 7793357
什么是DOI,文献DOI怎么找? 3437385
关于科研通互助平台的介绍 2560783
邀请新用户注册赠送积分活动 2484193